Nintedanib Eugia (Nintedanib)

Nintedanib Eugia acts on multiple receptor tyrosine kinases involved in fibrotic and oncogenic pathways, providing therapeutic benefit in several serious lung conditions.

• Idiopathic pulmonary fibrosis: slows decline in lung function and reduces disease progression.
• Systemic sclerosis‑associated interstitial lung disease: mitigates fibrotic changes and preserves respiratory capacity.
• Non‑small cell lung cancer: used in combination regimens to inhibit tumor growth and angiogenesis.

• Nintedanib inhibits a spectrum of receptor tyrosine kinases—including VEGFR 1‑3, PDGFR α/β, and FGFR 1‑3—thereby reducing fibroblast proliferation, migration, and differentiation. This multi‑target blockade curtails pathological angiogenesis and extracellular matrix deposition, slowing the progression of fibrosis and tumor vascularization.

Nintedanib may cause a range of adverse reactions, from mild to severe. Patients should be monitored regularly for any new symptoms.

Common Side Effects

• Diarrhea: frequent loose stools, often mild to moderate.
• Nausea and vomiting: gastrointestinal discomfort.
• Abdominal pain: cramping or discomfort in the stomach area.
• Decreased appetite: reduced desire to eat, potentially leading to weight loss.
• Elevated liver enzymes: mild increases in ALT/AST.
• Fatigue: general feeling of tiredness.

Serious or Rare Side Effects

• Severe liver injury: jaundice, marked enzyme elevation, or hepatic failure.
• Major bleeding events: gastrointestinal or intracranial hemorrhage.
• Cardiovascular complications: myocardial infarction or stroke.
• Gastrointestinal perforation: severe abdominal pain requiring urgent care.
• Severe infections: opportunistic or bacterial infections.
• Pulmonary embolism: sudden shortness of breath or chest pain.

Before initiating therapy, clinicians should evaluate patient-specific risk factors and monitor relevant clinical parameters.

• Liver function monitoring: check ALT/AST before treatment and periodically thereafter.
• Bleeding risk assessment: avoid in patients with active bleeding or uncontrolled anticoagulation.
• Cardiovascular evaluation: caution in patients with recent myocardial infarction or uncontrolled hypertension.
• Pregnancy and lactation: avoid use due to unknown safety; discuss contraception.
• Renal impairment: dose adjustment may be required in severe renal dysfunction.
• Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Nintedanib can interact with several drug classes, influencing its efficacy and safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase nintedanib exposure.
• Potent P‑gp inhibitors (e.g., verapamil): can raise plasma concentrations.
• Anticoagulants (e.g., warfarin, direct oral anticoagulants): heightened risk of serious bleeding.

Moderate Interactions (Monitor Closely)

• Moderate CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic effect.
• Antiplatelet agents (e.g., aspirin, clopidogrel): monitor for additive bleeding risk.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase gastrointestinal bleeding potential.